| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.70▼ | 1.71▼ | 1.74▼ | 1.74▼ | 1.74▼ |
| MA10 | 1.73▼ | 1.74▼ | 1.75▼ | 1.78▼ | 1.85▼ |
| MA20 | 1.76▼ | 1.75▼ | 1.74▼ | 1.77▼ | 2.04▼ |
| MA50 | 1.75▼ | 1.79▼ | 1.82▼ | 1.92▼ | 1.31▲ |
| MA100 | 1.82▼ | 1.80▼ | 1.77▼ | 2.05▼ | 1.04▲ |
| MA200 | 1.77▼ | 1.88▼ | 1.96▼ | 1.46▲ | 1.51▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.009▼ | -0.005▼ | -0.002▼ | -0.003▼ | -0.103▼ |
| RSI | 39.397▼ | 40.479▼ | 41.712▼ | 42.459▼ | 47.848▼ |
| STOCH | 5.556▼ | 15.556▼ | 28.148 | 11.030▼ | 17.270▼ |
| WILL %R | -86.667▼ | -86.667▼ | -86.667▼ | -97.717▼ | -86.615▼ |
| CCI | -100.346▼ | -118.808▼ | -107.692▼ | -80.510 | -88.206 |
|
Thursday, August 07, 2025 01:26 PM
IN8bio is developing a platform of cell therapies using gamma-delta T cells, a type of immune cell believed to help target and destroy cancer cells. Its current lead programs include INB-200 for ...
|
|
Monday, June 02, 2025 04:41 AM
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
|
|
Tuesday, March 18, 2025 05:12 AM
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and autoimmune diseases, will participate in the Immuno-Oncology 360° Conference 2025 from ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 12/12/25 | 1.76 | 1.87 | 1.67 | 1.68 | 86,115 |
| 11/12/25 | 1.76 | 1.79 | 1.71 | 1.73 | 32,085 |
| 10/12/25 | 1.70 | 1.80 | 1.70 | 1.77 | 39,157 |
| 09/12/25 | 1.77 | 1.79 | 1.70 | 1.72 | 40,676 |
| 08/12/25 | 1.82 | 1.8285 | 1.77 | 1.78 | 26,476 |
| 05/12/25 | 1.85 | 1.8899 | 1.76 | 1.77 | 26,186 |
| 04/12/25 | 1.78 | 1.84 | 1.76 | 1.82 | 36,168 |
| 03/12/25 | 1.80 | 1.81 | 1.73 | 1.75 | 20,426 |
| 02/12/25 | 1.95 | 1.97 | 1.77 | 1.78 | 62,268 |
| 01/12/25 | 2.05 | 2.108 | 1.95 | 1.96 | 68,065 |
|
|
||||
|
|
||||
|
|